Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
New Advances and Perspectives in Nanotechnology for the Treatment of...
share announcement

New Advances and Perspectives in Nanotechnology for the Treatment of Cancer Cells

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Methods".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 3103

Special Issue Editor

Dr. Karuppusamy Shanmugapriya

E-Mail Website
Guest Editor
School of Biosystems and Food Engineering, University College Dublin, Belfield, D04 V1W8 Dublin, Ireland
Interests: nanotechnology; immunotherapeutics; cancer biotherapeutics; proliferation; regulating factors; cell culture; biomedical application; nutraceuticals; cancer treatment

Special Issue Information

Dear Colleagues,

In recent decades, nanotechnology has already had a great impact on cancer detection and therapy. The application of nanotechnology to the healthcare aspects of biomedicine is rapidly progressing in advanced treatment strategies, particularly in the detection and monitoring of cancer progression and treatment in the field of cancer biotherapeutics. This type of cutting-edge technology in the current pharmaceutical industry is manifested by a recently developed nanomedicine approach to the treatment various types of cancer, advances that have unlocked new abilities in developed datasets to provide biological insight into cancer.
In the Special Issue of Cells, entitled “New Advance and perspectives in Nanotechnology for the Treatment of Cancer Cells”, we would like to showcase current advances in the field of nanotechnology and related approaches to the study of cancer detection and treatment. This applies is related to advances in underlying technologies, as well as those relating to key biological and therapeutic findings. Potential topics include, but are not limited to, nanotechnology research with a cancer focus involving the development of nanotechnology methods, nanotechnology-based biological and clinical findings, small-molecule and immunotherapeutic target discovery, therapeutic mechanisms of action, cancer immunology, advancements in sample preparation techniques, single-cell analysis, comprehensive metadata analysis, AI/statistics technology, etc. The perspectives for new advances/developments in cancer biotherapeutics directing to the clinical approaches of therapeutic drug delivery by nanotechnology and based approaches will be addressed. Interdisciplinary research is highly valued and encouraged. We welcome the submission of both original research articles and reviews.

Dr. Karuppusamy Shanmugapriya
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • immunotherapeutics
  • cancer biotherapeutics
  • proliferation
  • regulating factors
  • cell culture
  • biomedical application
  • nutraceuticals
  • cancer treatment

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 3737 KiB  
Article
Green-Synthesized Silver and Selenium Nanoparticles Using Berberine: A Comparative Assessment of In Vitro Anticancer Potential on Human Hepatocellular Carcinoma Cell Line (HepG2)
by Azza M. Khaled, Mohamed S. Othman, Sofian T. Obeidat, Ghada M. Aleid, Shimaa M. Aboelnaga, Alaa Fehaid, Heba M. R. Hathout, Ashraf A. Bakkar, Ahmed E. Abdel Moneim, Islam M. El-Garawani and Dalia S. Morsi
Cells 2024, 13(3), 287; https://doi.org/10.3390/cells13030287 - 5 Feb 2024
Viewed by 1285
Abstract
A well-known natural ingredient found in several medicinal plants, berberine (Ber), has been shown to have anticancer properties against a range of malignancies. The limited solubility and bioavailability of berberine can be addressed using Ber-loaded nanoparticles. In this study, we compared the in [...] Read more.
A well-known natural ingredient found in several medicinal plants, berberine (Ber), has been shown to have anticancer properties against a range of malignancies. The limited solubility and bioavailability of berberine can be addressed using Ber-loaded nanoparticles. In this study, we compared the in vitro cytotoxic effects of both Ber-loaded silver nanoparticles (Ber-AgNPs) and Ber-loaded selenium nanoparticles (Ber-SeNPs) in the human liver cancer cell line (HepG2) and mouse normal liver cells (BNL). The IC50 values in HepG2 for berberine, Ber-AgNPs, Ber-SeNPs, and cisplatin were 26.69, 1.16, 0.04, and 0.33 µg/mL, respectively. Our results show that Ber and its Ag and Se nanoparticles exerted a good antitumor effect against HepG2 cells by inducing apoptosis via upregulating p53, Bax, cytosolic cytochrome C levels, and caspase-3 activity, and the down-regulation of Bcl-2 levels. Similarly, incubation with Ber and both Ber-NPs (Ag and Se) led to a significant dose-dependent elevation in inflammatory markers’ (TNF-α, NF-κB, and COX-2) levels compared to the control group. In addition, it led to the arrest of the G1 cell cycle by depleting the expression of cyclin D1 and CDK-2 mRNA. Furthermore, Ber and both Ber-NPs (Ag and Se) caused a significant dose-dependent increase in LDH activity in HepG2 cells. Furthermore, our findings offer evidence that Ber and its nanoparticles intensified oxidative stress in HepG2 cells. Furthermore, the migration rate of cells subjected to berberine and its nanoforms was notably decreased compared to that of control cells. It can be inferred that Ber nanoparticles exhibited superior anticancer efficacy against HepG2 compared to unprocessed Ber, perhaps due to their improved solubility and bioavailability. Furthermore, Ber-SeNPs exhibited greater efficacy than Ber-AgNPs, possibly as a result of the inherent anticancer characteristics of selenium. Full article
(This article belongs to the Special Issue New Advances and Perspectives in Nanotechnology for the Treatment of Cancer Cells)
►▼ Show Figures

Figure 1

12 pages, 1133 KiB  
Article
Exploring the Potential of Montmorillonite as an Antiproliferative Nanoagent against MDA-MB-231 and MCF-7 Human Breast Cancer Cells
by Alireza Ghannad Sabzevari, Hossein Sabahi, Mohsen Nikbakht, Mehdi Azizi, Hassan Dianat-Moghadam and Zohreh Amoozgar
Cells 2024, 13(2), 200; https://doi.org/10.3390/cells13020200 - 22 Jan 2024
Viewed by 1343
Abstract
Unlike MCF-7 cells, MDA-MB-231 cells are unresponsive to hormone therapy and often show resistance to chemotherapy and radiotherapy. Here, the antiproliferative effect of biocompatible montmorillonite (Mt) nanosheets on MDA-MB-231 and MCF-7 human breast cancer cells was evaluated by MTT assay, flow cytometry, and [...] Read more.
Unlike MCF-7 cells, MDA-MB-231 cells are unresponsive to hormone therapy and often show resistance to chemotherapy and radiotherapy. Here, the antiproliferative effect of biocompatible montmorillonite (Mt) nanosheets on MDA-MB-231 and MCF-7 human breast cancer cells was evaluated by MTT assay, flow cytometry, and qRT-PCR. The results showed that the Mt IC50 for MDA-MB-231 and MCF-7 cells in a fetal bovine serum (FBS)-free medium was ~50 and ~200 µg/mL, and in 10% FBS medium ~400 and ~2000 µg/mL, respectively. Mt caused apoptosis in both cells by regulating related genes including Cas-3, P53, and P62 in MDA-MB-231 cells and Bcl-2, Cas-8, Cas-9, P53, and P62 in MCF-7 cells. Also, Mt arrested MCF-7 cells in the G0/G1 phase by altering Cyclin-D1 and P21 expression, and caused sub-G1 arrest and necrosis in both cells, possibly through damaging the mitochondria. However, fewer gene expression changes and more sub-G1 arrest and necrosis were observed in MDA-MB-231 cells, confirming the higher vulnerability of MDA-MB-231 cells to Mt. Furthermore, MDA-MB-231 cells appeared to be much more vulnerable to Mt compared to other cell types, including normal lung fibroblast (MRC-5), colon cancer (HT-29), and liver cancer (HepG2) cells. The higher vulnerability of MDA-MB-231 cells to Mt was inferred to be due to their higher proliferation rate. Notably, Mt cytotoxicity was highly dependent on both the Mt concentration and serum level, which favors Mt for the local treatment of MDA-MB-231 cells. Based on these results, Mt can be considered as an antiproliferative nanoagent against MDA-MB-231 cells and may be useful in the development of local nanoparticle-based therapies. Full article
(This article belongs to the Special Issue New Advances and Perspectives in Nanotechnology for the Treatment of Cancer Cells)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop